213685-64-4

Basic information

• Product Name: 2-Mercapto-benzooxazole-7-carboxylic acid Methyl ester
• Synonyms: 2-Mercapto-benzooxazole-7-carboxylic acid Methyl ester
• CAS NO: 213685-64-4
• Molecular Formula: C₉H₇NO₃S
• Molecular Weight: 209.22178
• Mol File: 213685-64-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Mercapto-benzooxazole-7-carboxylic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Mercapto-benzooxazole-7-carboxylic acid Methyl ester(213685-64-4)
• EPA Substance Registry System: 2-Mercapto-benzooxazole-7-carboxylic acid Methyl ester(213685-64-4)

Safety Data

• Hazardous Substances Data: 213685-64-4(Hazardous Substances Data)

Upstream product

• 35748-34-6 methyl 3-aminosalicylate 
• 140-89-6 potassium ethyl xanthogenate 
• 570-23-0 3-aminosalicylic acid 
• 67-56-1 methanol 

Downstream Products

• 213685-11-1 N-(2,6-diisopropylphenyl)-N'-[7-(7-methoxycarbonylbenzoxazol-2-ylthio)heptyl]urea 
• 213685-27-9 N-(2,6-diisopropylphenyl)-N'-heptyl-N'-[6-(7-methoxycarbonylbenzoxazol-2-ylthio)hexyl]urea 
• 213685-03-1 2-((6-((2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazole-7-carboxylic acid 
• 213685-04-2 N-(2,6-diisopropylphenyl)-6-((7-(hydroxymethyl)benzo[d]oxazol-2-yl)thio)hexanamide 
• 213685-05-3 N-(2,6-diisopropylphenyl)-6-((7-((N,N-dimethylamino)methyl)benzo[d]oxazol-2-yl)thio)hexanamide 
• 213685-85-9 t-butyl (2-((6-((N-2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazol-7-yl)carbamate 
• 213685-86-0 6-((7-aminobenzo[d]oxazol-2-yl)thio)-N-(2,6-diisopropylphenyl)hexanamide 
• 213685-02-0 methyl 2-((6-((2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazole-7-carboxylate 

Relevant articles and documents

Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors

We describe our molecular design of aortic-selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also abbreviated as SOAT) inhibitors, their structure–activity relationships (SARs) and their pharmacokinetic (PK) and pharmacological profiles. The connection of two weak ligands—N-(2,6-diisopropylphenyl)acetamide (50% inhibitory concentration [IC50] = 8.6 μM) and 2-(methylthio)benzo[d]oxazole (IC50 = 31 μM)—via a linker comprising a 6 methylene group chains yielded a highly potent molecule, 9-(benzo[d]oxazol-2-ylthio)-N-(2,6-diisopropylphenyl)nonanamide (3h) that exhibited high potency (IC50 = 0.004 μM) toward aortic ACAT. This head-to-tail design made it possible to markedly enhance the activity to 2150- to 7750-fold and to discriminate the isoform-selectivity based on the double-induced fit mechanism. At doses of 1 and 3 mg/kg, 3h significantly decreased the lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3h in vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1 overexpression.

Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives

This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

FKBP inhibitors

Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.